Research progress of hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of renal anemia and ischemic heart disease
10.3760/cma.j.cn101721-20220606-000226
- VernacularTitle:脯氨酸羟化酶抑制剂治疗肾性贫血和缺血性心脏病的研究进展
- Author:
Haoqi SUN
1
;
Zhentao GUO
;
Xiangming WANG
;
Jingying WANG
Author Information
1. 潍坊医学院临床医学院，潍坊 261053
- Keywords:
Hypoxic inducible factor;
Hypoxia-inducible factor-prolyl hydroxylase inhibitors;
Chronic kidney disease anemia;
Ischemic heart disease
- From:
Clinical Medicine of China
2022;38(5):475-480
- CountryChina
- Language:Chinese
-
Abstract:
The hypoxia-inducible factor is a significant regulator of adaptive transcriptional response in hypoxia or hypoxia. Hypoxia-inducible factor (hypoXIA-inducible factor) loses its activity after hydroxylation by proline hydroxylase in a normoxic environment. Proline hydroxylase inhibitor is a kind of new small molecule oral preparation by inhibiting the proline hydroxylase, reducing the degradation of HIF, activating the hypoxia-induced way, adjusting including stimulates erythropoiesis, iron absorption and mobilization, angiogenesis, lipid, and glucose metabolism, inflammation, energy metabolism, cell growth and differentiation, and other physiological reaction, Showed more clinical benefits. In recent years, the application of proline hydroxylase inhibitors in the field of renal anemia has achieved apparent efficacy, and the research in the field of ischemic heart disease has also made significant progress in the future in the treatment of ischemic heart disease and other aspects of good application prospects.
